Frostyyy的个人主页 - 老虎社区

Frostyyy

暂无个人介绍

IP属地：未知

10关注

3粉丝

0主题

0勋章

2021-12-07

EV to the moon

抱歉，原内容已删除

2021-12-02

Not the time yet

2021 was the year of the metaverse, but it will be years before it's a reality

2021-11-16

Pls drop so that i can buy more

Nvidia Became A Meme Stock And Is Overvalued By At Least 50 Percent For The Coming Decade

2021-11-03

To the moon!!

抱歉，原内容已删除

2021-11-02

Go go go!!!

Novavax shares jumped another 4.4% in premarket trading

2021-10-22

$AMD(AMD)$ up up up!!!

2021-10-20

Gg overpromise again

抱歉，原内容已删除

2021-10-19

Very good

抱歉，原内容已删除

2021-10-06

But why stock price still drop??

抱歉，原内容已删除

2021-10-06

why sell???

Novavax CEO Stanley Erck sells ~92K shares as part of trading plan

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":3581131361771943,"uuid":"3581131361771943","gmtCreate":1618276998852,"gmtModify":1618276998852,"name":"Frostyyy","pinyin":"frostyyy","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":3,"headSize":10,"tweetSize":17,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.09","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"60.24%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":606853487,"gmtCreate":1638861086065,"gmtModify":1638861086179,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"EV to the moon","listText":"EV to the moon","text":"EV to the moon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606853487","repostId":"2189682681","repostType":4,"isVote":1,"tweetType":1,"viewCount":489,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603619690,"gmtCreate":1638404643257,"gmtModify":1638404643467,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Not the time yet","listText":"Not the time yet","text":"Not the time yet","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/603619690","repostId":"2188690505","repostType":4,"repost":{"id":"2188690505","pubTimestamp":1638402719,"share":"https://www.laohu8.com/m/news/2188690505?lang=&edition=full","pubTime":"2021-12-02 07:51","market":"us","language":"en","title":"2021 was the year of the metaverse, but it will be years before it's a reality","url":"https://stock-news.laohu8.com/highlight/detail?id=2188690505","media":"Yahoo Finance","summary":"Big Tech wants to sell you on the metaverse, but don’t hold your breath.\nIf there’s one buzzword the","content":"<p><b>Big Tech wants to sell you on the metaverse, but don’t hold your breath.</b></p>\n<p>If there’s <a href=\"https://laohu8.com/S/AONE.U\">one</a> buzzword the tech world couldn’t stop using in 2021, it was metaverse. Well, that and NFTs, but let’s talk about tech CEOs’ fixation on the metaverse.</p>\n<p>Microsoft (MSFT), Nvidia (NVDA), and, of course, Facebook (FB), er, Meta, each laid out elaborate plans this year for a new version of the internet, one that features 3-D online worlds where people can connect as if they were talking to each other in real life.</p>\n<p>To hear today’s CEOs talk about it, the metaverse will be the next evolution of the internet. Just as we went from chatting on message boards on chunky laptops to buying homes on our smartphones, tech leaders say, the metaverse will transform the way we use the web. We’re talking walking around a fully virtual world as if you were really there, or dropping in on colleagues to host a meeting thousands of miles away.</p>\n<p>If that’s all very sci-fi sounding, it’s because it is. To be sure, we’ve seen glimpses of the metaverse in the form of Microsoft’s upcoming Teams Mesh that lets you use a digital avatar in virtual meetings or Nvidia’s Omniverse, which helps teach AI-powered cars to drive.</p>\n<p>But the metaverse as tech visionaries describe it — where you can appear as a hologram in your friend’s special AR goggles and play tennis in real-time — is still years away from reality.</p>\n<h2><b>We’re witnessing an incredible advertising effort</b></h2>\n<p>Let’s start with the metaverse we’ve been promised so far. If you take Facebook, dang, force of habit, I mean Meta’s version of the metaverse, we’ll be able to fluidly transport ourselves across different virtual worlds. One minute you’re playing chess while floating several feet above the table; the next, you’re hanging ten with your friend on the open water.</p>\n<p>But Meta’s demonstration was more fantasy than true metaverse tech. It was a video meant to provide consumers, and investors, with a glimpse at what the company hopes to build.</p>\n<p>“It's going to take a lot of time,” explained Stanford University Jeremy Bailenson, who teaches a class completely in virtual reality. “We're not all going to be wearing headsets or glasses anytime soon.”</p>\n<p>Bailenson, whose students spent a collective 200,000 minutes in VR headsets in recent months, says nothing has truly changed in terms of the technology recently. Instead, what we’re seeing is a massive marketing campaign by companies that are hyped on the metaverse.</p>\n<h2><b>The technology is still in its infancy</b></h2>\n<p>The metaverse of Mark Zuckerberg’s dreams will require infrastructure that allows consumers to swiftly travel among 3-D worlds. We’re also going to need headgear that isn’t awful.</p>\n<p>I’ve used the majority of commercially available headsets, not to mention a few that are meant for industrial use, and they're all uncomfortable. If they’re not heavy, they don’t properly fit over glasses. Or they leave you sweating. What’s worse, if they’re not tethered to a high-end PC, which costs plenty on its own, they have short battery lives.</p>\n<p class=\"t-img-caption\"><img src=\"https://s.yimg.com/os/creatr-uploaded-images/2021-11/7c01d6a0-3cc2-11ec-bfc5-4088a6081088\" tg-width=\"3017\" tg-height=\"1814\" referrerpolicy=\"no-referrer\"><span>Meta's next-generation headset, Cambria, will be able to read and understand users' facial expressions. (Image: Meta)Meta</span></p>\n<p>On top of that, the visual fidelity of your average headset is nowhere near that of, say, a 4K TV. Fine details are lost in the screen door effect caused by the fact that the headsets’ displays aren’t high enough resolution to perfectly blend each pixel together.</p>\n<p>Then there are the headaches and nausea that plague some headset users.</p>\n<p>And that’s just the headgear. For a fully immersive experience that tech companies are pitching, you’ll need to be able to feel pressure and resistance, which will require if not specialized gloves then some kind of ... suit?</p>\n<p>All of that is to say that, while consumers can have fun in VR headsets, we’re nowhere near experiencing the kind of incredible 3-D world you’d expect from the book “Ready Player One.”</p>\n<h2><b>The metaverse has promise</b></h2>\n<p>That’s not to knock the metaverse or its potential entirely. Bailenson’s class, for instance, is able to learn about therapeutic medicines and empathy for others by virtually walking in their shoes.</p>\n<p>Nvidia’s Omniverse, which the company positions as plumbing for the larger metaverse, has shown impressive promise by helping predict forest fires and serving as a test bed for the artificial intelligence that will eventually power the company’s self-driving car capabilities.</p>\n<p class=\"t-img-caption\"><img src=\"https://s.yimg.com/os/creatr-uploaded-images/2021-11/919bdce0-40d7-11ec-bffb-ce6346beed4d\" tg-width=\"1600\" tg-height=\"900\" referrerpolicy=\"no-referrer\"><span>Nidia's is using its Omniverse and AI technologies to build out self-driving car capabilities. (Image: Nvidia)Nvidia</span></p>\n<p>Microsoft’s Teams Mesh, still in its early stages, could make it less stressful to join virtual meetings by letting you skip your webcam and use a digital avatar to chat with colleagues instead. Just imagine never having to comb your hair, or beard in my case, before a virtual meeting again.</p>\n<p>Roblox (RBLX) and Epic’s “Fortnite” have also laid the foundation for what early metaverses can offer, creating virtual worlds where users can spend time with friends and attend concerts together whether they’re separated by tens or thousands of miles.</p>\n<p>What we’re seeing is the very start of what could turn into the kind of metaverse Big Tech promises with its flashy advertising efforts and videos.</p>\n<p>But without grounding those wild dreams they’re pushing in some kind of reality, tech firms run the risk of alienating their own users, and turning the entire concept of the metaverse into a passing fad that never truly takes off.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2021 was the year of the metaverse, but it will be years before it's a reality</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2021 was the year of the metaverse, but it will be years before it's a reality\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-02 07:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/2021-was-the-year-of-the-metaverse-but-itll-take-years-before-its-a-reality-170559280.html><strong>Yahoo Finance</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Big Tech wants to sell you on the metaverse, but don’t hold your breath.\nIf there’s one buzzword the tech world couldn’t stop using in 2021, it was metaverse. Well, that and NFTs, but let’s talk about...</p>\n\n<a href=\"https://finance.yahoo.com/news/2021-was-the-year-of-the-metaverse-but-itll-take-years-before-its-a-reality-170559280.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4554":"元宇宙及AR概念","NVDA":"英伟达","BK4532":"文艺复兴科技持仓","BK4553":"喜马拉雅资本持仓","BK4567":"ESG概念","BK4534":"瑞士信贷持仓","BK4507":"流媒体概念","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4566":"资本集团","RBLX":"Roblox Corporation","BK4525":"远程办公概念","MSFT":"微软","BK4508":"社交媒体","BK4524":"宅经济概念","BK4535":"淡马锡持仓","BK4543":"AI","BK4527":"明星科技股","BK4077":"互动媒体与服务","BK4538":"云计算","BK4550":"红杉资本持仓","BK4141":"半导体产品","BK4503":"景林资产持仓","BK4551":"寇图资本持仓","BK4547":"WSB热门概念","BK4097":"系统软件","BK4504":"桥水持仓","BK4085":"互动家庭娱乐","BK4549":"软银资本持仓","BK4548":"巴美列捷福持仓","BK4565":"NFT概念","BK4529":"IDC概念","BK4528":"SaaS概念","BK4516":"特朗普概念"},"source_url":"https://finance.yahoo.com/news/2021-was-the-year-of-the-metaverse-but-itll-take-years-before-its-a-reality-170559280.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2188690505","content_text":"Big Tech wants to sell you on the metaverse, but don’t hold your breath.\nIf there’s one buzzword the tech world couldn’t stop using in 2021, it was metaverse. Well, that and NFTs, but let’s talk about tech CEOs’ fixation on the metaverse.\nMicrosoft (MSFT), Nvidia (NVDA), and, of course, Facebook (FB), er, Meta, each laid out elaborate plans this year for a new version of the internet, one that features 3-D online worlds where people can connect as if they were talking to each other in real life.\nTo hear today’s CEOs talk about it, the metaverse will be the next evolution of the internet. Just as we went from chatting on message boards on chunky laptops to buying homes on our smartphones, tech leaders say, the metaverse will transform the way we use the web. We’re talking walking around a fully virtual world as if you were really there, or dropping in on colleagues to host a meeting thousands of miles away.\nIf that’s all very sci-fi sounding, it’s because it is. To be sure, we’ve seen glimpses of the metaverse in the form of Microsoft’s upcoming Teams Mesh that lets you use a digital avatar in virtual meetings or Nvidia’s Omniverse, which helps teach AI-powered cars to drive.\nBut the metaverse as tech visionaries describe it — where you can appear as a hologram in your friend’s special AR goggles and play tennis in real-time — is still years away from reality.\nWe’re witnessing an incredible advertising effort\nLet’s start with the metaverse we’ve been promised so far. If you take Facebook, dang, force of habit, I mean Meta’s version of the metaverse, we’ll be able to fluidly transport ourselves across different virtual worlds. One minute you’re playing chess while floating several feet above the table; the next, you’re hanging ten with your friend on the open water.\nBut Meta’s demonstration was more fantasy than true metaverse tech. It was a video meant to provide consumers, and investors, with a glimpse at what the company hopes to build.\n“It's going to take a lot of time,” explained Stanford University Jeremy Bailenson, who teaches a class completely in virtual reality. “We're not all going to be wearing headsets or glasses anytime soon.”\nBailenson, whose students spent a collective 200,000 minutes in VR headsets in recent months, says nothing has truly changed in terms of the technology recently. Instead, what we’re seeing is a massive marketing campaign by companies that are hyped on the metaverse.\nThe technology is still in its infancy\nThe metaverse of Mark Zuckerberg’s dreams will require infrastructure that allows consumers to swiftly travel among 3-D worlds. We’re also going to need headgear that isn’t awful.\nI’ve used the majority of commercially available headsets, not to mention a few that are meant for industrial use, and they're all uncomfortable. If they’re not heavy, they don’t properly fit over glasses. Or they leave you sweating. What’s worse, if they’re not tethered to a high-end PC, which costs plenty on its own, they have short battery lives.\nMeta's next-generation headset, Cambria, will be able to read and understand users' facial expressions. (Image: Meta)Meta\nOn top of that, the visual fidelity of your average headset is nowhere near that of, say, a 4K TV. Fine details are lost in the screen door effect caused by the fact that the headsets’ displays aren’t high enough resolution to perfectly blend each pixel together.\nThen there are the headaches and nausea that plague some headset users.\nAnd that’s just the headgear. For a fully immersive experience that tech companies are pitching, you’ll need to be able to feel pressure and resistance, which will require if not specialized gloves then some kind of ... suit?\nAll of that is to say that, while consumers can have fun in VR headsets, we’re nowhere near experiencing the kind of incredible 3-D world you’d expect from the book “Ready Player One.”\nThe metaverse has promise\nThat’s not to knock the metaverse or its potential entirely. Bailenson’s class, for instance, is able to learn about therapeutic medicines and empathy for others by virtually walking in their shoes.\nNvidia’s Omniverse, which the company positions as plumbing for the larger metaverse, has shown impressive promise by helping predict forest fires and serving as a test bed for the artificial intelligence that will eventually power the company’s self-driving car capabilities.\nNidia's is using its Omniverse and AI technologies to build out self-driving car capabilities. (Image: Nvidia)Nvidia\nMicrosoft’s Teams Mesh, still in its early stages, could make it less stressful to join virtual meetings by letting you skip your webcam and use a digital avatar to chat with colleagues instead. Just imagine never having to comb your hair, or beard in my case, before a virtual meeting again.\nRoblox (RBLX) and Epic’s “Fortnite” have also laid the foundation for what early metaverses can offer, creating virtual worlds where users can spend time with friends and attend concerts together whether they’re separated by tens or thousands of miles.\nWhat we’re seeing is the very start of what could turn into the kind of metaverse Big Tech promises with its flashy advertising efforts and videos.\nBut without grounding those wild dreams they’re pushing in some kind of reality, tech firms run the risk of alienating their own users, and turning the entire concept of the metaverse into a passing fad that never truly takes off.","news_type":1},"isVote":1,"tweetType":1,"viewCount":720,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":871185699,"gmtCreate":1637037132655,"gmtModify":1637037302349,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Pls drop so that i can buy more","listText":"Pls drop so that i can buy more","text":"Pls drop so that i can buy more","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/871185699","repostId":"1160740007","repostType":4,"repost":{"id":"1160740007","pubTimestamp":1637034481,"share":"https://www.laohu8.com/m/news/1160740007?lang=&edition=full","pubTime":"2021-11-16 11:48","market":"us","language":"en","title":"Nvidia Became A Meme Stock And Is Overvalued By At Least 50 Percent For The Coming Decade","url":"https://stock-news.laohu8.com/highlight/detail?id=1160740007","media":"seekingalpha","summary":"Summary\n\nThere is no such thing as eternal dominance, especially not in the innovation- and competit","content":"<p>Summary</p>\n<ul>\n <li>There is no such thing as eternal dominance, especially not in the innovation- and competition-driven tech sector.</li>\n <li>In my view, Nvidia does not offer a good risk/reward ratio as an investment for the next five to ten years.</li>\n <li>At its current price, the stock is overvalued for the next few years and offers nothing more than a massive downside potential of more than 50 percent.</li>\n</ul>\n<p><b>Introduction</b></p>\n<p>Nvidia's (NVDA) share price has followed a parabolic trend over the last few weeks, even in a logarithmic chart. In addition to the prolonged growth that accompanied the general optimistic stock market sentiment and the hype around tech stocks, we now see a short-term growth spurt. However, with the recent growth that has carried the company to a market cap of $760 billion, the stock has finally become a speculative bubble, joining all the other meme stocks. Thus, with Nvidia, I think we see how little an excellent business model has to do with an excellent investment. At its current price, the stock is overvalued for the next few years and offers nothing more than a massive downside potential of more than 50 percent.</p>\n<p>Nothing but expectations</p>\n<p>Recently, hype sentiment has carried the share upwards. For this hype sentiment, theMetaverse/Omniverse, AI, and the Arm deal were the main reasons for exuberant optimism among Nvidia bulls.</p>\n<p>The company created a lot of excitement around its appearance at the GTC conference and the introduction of the omniverse platform. With this platform, Nvidia wants to create virtual worldsin particular:</p>\n<blockquote>\n Omniverse - a platform that serves as the connective tissue for physically accurate 3D virtual worlds - is gaining new features such as AR, VR and multi-GPU rendering, as well as integrations for infrastructure and industrial digital-twin applications with software from Bentley Systems and Esri.\n</blockquote>\n<blockquote>\n Omniverse enables engineers and designers to build physically accurate digital twins of buildings and products, or create massive, true-to-reality simulation environments for training robots or autonomous vehicles before they're deployed in the physical world.\n</blockquote>\n<p>The goal behind Omniverse is to create an ecosystem that is used by many industries worldwide. What is particularly exciting is that companies can create virtual twins of reality. The areas of application are manifold. For example, companies can test their products in this virtual world. It doesn't matter whether it's telecommunications companies that want to try the range of their transmission towers or data connection tools or car manufacturers that want to test the characteristics of cars in a real-life virtual environment. Instead of driving on a test track, the tests can take place in a virtual world. Awesome!</p>\n<p>What bugs me about this, however, are the many buzzwords. All these flowering words about quantum computers, AI, cyber security, etc., run through the entire (but otherwise fascinating and worth seeing) presentation. Of course, investors always need to clean up such presentations of all the advertising and touting to grasp the realistic opportunities. In the end, I think we are getting into the future that Nvidia is drawing for us. It may look different here and there, but the opportunities and monetization possibilities around virtual reality or virtual twins will be enormous and catapult us into the post-Internet age.</p>\n<p>But that brings us to the point. You don't have to have owned Microsoft (MSFT) shares in 2000 to see the parallels. With Microsoft, as with many Internet stocks, there was great euphoria about the future of the Internet and the associated (disruptive)business opportunities:</p>\n<blockquote>\n Before the dot.com or tech bubble burst, investors were convinced of the possibilities of the Internet, digitalization, and technical progress. Microsoft, it seemed, was the gatekeeper to this world with its Windows operating system and the Internet Explorer. The investors saw themselves at the beginning of a vast cycle. And Microsoft was able to keep its promises. By 1999, the company had increased its annual revenue by 30%. Besides, Microsoft was profitable even then and was able to increase its profits more than five-fold from 1995 to 2000.\n</blockquote>\n<blockquote>\n <img src=\"https://static.tigerbbs.com/60a717d69de6b7f73e2ac4764f6e2d5f\" tg-width=\"640\" tg-height=\"150\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\">\n</blockquote>\n<blockquote>\n <i>Microsoft revenue &amp; EPS from 1995-2001; taken from MSFT investor relation/graph by author</i>\n</blockquote>\n<blockquote>\n But then, the bubble started to burst, and Judge Thomas Penfield Jacksondecidedthat Microsoft had violated the Sherman Antitrust Act due to abusive behavior, which only accelerated the bursting of the tech bubble. You know the rest of the story.\n</blockquote>\n<p>As with Microsoft in the dot.com bubble, the problem I see with Nvidia is that investors are euphorically betting on something that does not yet exist. So much of this future is currently priced into the share price without it even being clear what will end up in shareholders' pockets in the form of profits, cash flows, or dividends. Think of all the dot.com bubbles that burst even though companies like Cisco (CSCO) or Microsoft could deliver on their growth promises. Here we see the classic difference between companies and investments. An investment in a terrific company can still be a bad investment if the price is too high. If investors now buy Nvidia because of the Omniverse, it is nothing but a big gamble.</p>\n<p>And then, of course, there is Nvidia's classic business around the GPU and the Tegra processors. Here Nvidia is very successful. But this business is anything but a moat. Yes, Nvidia was able to increase sales and profits with it massively. The company has benefited primarily from the fact that the architecture of GPUs is superior to that of pure CPUs, such as those offered by Intel (INTC), for many applications such as high-performance computing, gaming, and servers.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f665c228fc6b50397b6fe547b6c1dbb3\" tg-width=\"640\" tg-height=\"322\" width=\"100%\" height=\"auto\"><span>Source:Investor presentation</span></p>\n<p>Now Nvidia is looking to gain a foothold in the CPU market with the $40 billion Arm acquisition, using Arm's business model to secure the company's licenses. The Arm architecture is a key technology, especially for the entire smartphone industry. Arm is the architecture behind the SoCs used in virtually all smartphones and most tablet computers.</p>\n<p>But it is not at all clear whether the deal will go through and at what price. Competition authorities such as the&nbsp;British CMA see considerable competition concerns&nbsp;and will presumably tie approval to significant concessions. Even if Nvidia does get clearance, the competition watchdogs will closely look at licensing practices. Unfortunately for Nvidia, and even though Arm does not make chips, the current chip shortage is prompting competition authorities to scrutinize the merger even more closely as the entire chip industry comes under scrutiny.</p>\n<p>In short, the Arm deal may ultimately bring more advantages than disadvantages for Nvidia, but it is uncertain to what extent advance praise is justified here. Investors should not forget that the competition is not sleeping. Qualcomm, in particular, is very active right now and has made a significant strategic move with the NUVIA acquisition. I have already written about NUVIAhereandhere, which Qualcomm acquired for $1.4 billion:</p>\n<blockquote>\n And then there's the startup NUVIA, which former Apple employees founded. CEO Amon wants to attack Apple's M1 processors with the acquired start-up and enter the laptop market next year. Qualcomm had previously tried integrating a smartphone SoC into a notebook with only minor modifications and okayish results.\n</blockquote>\n<blockquote>\n But now Qualcomm wants to release a Nuvia SoC based on ARM architecturenext year. This step would reduce Qualcomm's dependency on ARM and Nvidia enormously. Conversely, Qualcomm does not have much to lose since it can still license ARM technology from Nvidia in an emergency. The competition authorities will probably look particularly closely at the takeover of ARM by Nvidia to ensure that Nvidia does not put Qualcomm or other potential licensees at a disadvantage with too high license fees.\n</blockquote>\n<blockquote>\n The first comparisons of NUVIA's Phoenix chip to other chip suppliers already show a significant outperformance:\n</blockquote>\n<blockquote>\n <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/24cf0a0daa9c8b638e461a9bdaf0d1a9\" tg-width=\"640\" tg-height=\"407\" width=\"100%\" height=\"auto\"><span>Source:Nuvia Webpage</span></p>\n</blockquote>\n<p>Most recently, Qualcomm has been very optimistic about the prospects around the NUVIA deal:</p>\n<blockquote>\n We are pleased with the strong market validation of Arm-based personal computing in the industry transition to a new SoC architecture. We're more confident than ever in the connected computing opportunity, our upcoming solutions powered by our NUVIA CPUs, and our collaboration with Microsoft. We're also seeing increased traction in consumer electronics.\n</blockquote>\n<p>So it is not that Nvidia will single-handedly dominate the Arm market. The competitive pressure is no less in the other business areas either. Above all, the eternal GPU competitor AMD (AMD) will continue to put pressure on the company. In autonomous driving, Intel is a heavyweight competitor alongside Tesla (TSLA), following its acquisition of the Israeli companyMobileye for over $15 billion in 2017.</p>\n<p>Managing expectations</p>\n<p>With a P/E ratio of over 100, Nvidia would have to quadruple its profits to reach a valuation of 25, which is reasonable for a growth company. And admittedly, Nvidia has already achieved such growth.</p>\n<p>Nevertheless, investors who invest in Nvidia now are speculating that Nvidia will increase its profits in the same way for the coming years. Of course, the company has already managed such developments in the past. In 2005, Nvidia was able to push its earnings per share from $0.05 to $0.33 within three years, which corresponds to a six-fold increase. But already in 2009 and 2010, Nvidia made losses. Only in 2017, it was it able to lift EPS above the 2008 level. Investors have to face it: profit increases are not a one-way street, especially not in the tech sector. And even analysts do not expect Nvidia to increase profits fast enough to reach reasonable valuation levels based on the current share price over the following years. In 2020, adjusted EPS was $2.50. Below you see expected earnings for the subsequent years, and you can also see that even the most optimistic analyst out of 19 surveyed does not expect Nvidia to achieve EPS higher than $7.25 in 2024.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0d1916e5f56a5eee93d4c1c93e254afc\" tg-width=\"640\" tg-height=\"384\" width=\"100%\" height=\"auto\"><span>Source: www.dividendStocks.Cash</span></p>\n<p>So we are far from saying that Nvidia will reach reasonable multiples in the next 4, 5, or 6 years based on today's share price. Even if we set the fair P/E multiple at 40. Considering the expected earnings, this results in an overvaluation of almost 30% even until 2024.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/7635beca779966b95afc457e2942d3f3\" tg-width=\"640\" tg-height=\"340\" width=\"100%\" height=\"auto\"><span>Source: www.dividendStocks.Cash</span></p>\n<p>Even when looking at a DCF analysis, we see the apparent overvaluation and massive downside potential. Below you can see the expectations for the sales development until 2024.</p>\n<p><img src=\"https://static.tigerbbs.com/334c1692ae1a107d16b6c981312c34fb\" tg-width=\"635\" tg-height=\"417\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>For the DCF analysis, I even assume a much more optimistic scenario where the company will increase sales significantly higher. I also assume an improvement in margins.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0ff075390e6e0c070e102d3010f93296\" tg-width=\"640\" tg-height=\"391\" width=\"100%\" height=\"auto\"><span>Source:alphaspread.com/estimates by author</span></p>\n<p>Based on these figures and assuming a discount rate of 9%, we see that Nvidia is overvalued by 50 percent, which is essentially in line with the fundamental valuation.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/71fe4a0463babd595f753a0776e80efd\" tg-width=\"376\" tg-height=\"383\" width=\"100%\" height=\"auto\"><span>Source: alphaspread.com/estimates by author</span></p>\n<p>Investors should not forget that we could also see a change in interest rates next year. A discount rate of 9 percent could therefore be far too low. To remind you, the cost of equity was already 10 percent for Nvidia at the end of 2019. So what happens if we continue to take an optimistic growth scenario but increase the discount rate to 12 percent?</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1e8d3231ad0480f4042265afdcf2911d\" tg-width=\"640\" tg-height=\"226\" width=\"100%\" height=\"auto\"><span>Source:Discount rate history for Nvidia</span></p>\n<p>You can see the result here: The Nvidia share would then be overvalued by almost 75 percent.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4b3b3bab8c4014934702ed6382e76202\" tg-width=\"379\" tg-height=\"384\" width=\"100%\" height=\"auto\"><span>Source: alphaspread.com/estimates by author</span></p>\n<p>Conclusion</p>\n<p>There is no such thing as eternal dominance, especially not in the innovation- and competition-driven tech sector. In my view, Nvidia does not offer a good risk/reward ratio as an investment for the next five to ten years. At its current price, the stock is overvalued for the next few years and offers nothing more than a massive downside potential of more than 50 percent.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nvidia Became A Meme Stock And Is Overvalued By At Least 50 Percent For The Coming Decade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNvidia Became A Meme Stock And Is Overvalued By At Least 50 Percent For The Coming Decade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-16 11:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4469673-nvidia-overvalued-by-at-least-50-percent><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nThere is no such thing as eternal dominance, especially not in the innovation- and competition-driven tech sector.\nIn my view, Nvidia does not offer a good risk/reward ratio as an investment ...</p>\n\n<a href=\"https://seekingalpha.com/article/4469673-nvidia-overvalued-by-at-least-50-percent\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVDA":"英伟达"},"source_url":"https://seekingalpha.com/article/4469673-nvidia-overvalued-by-at-least-50-percent","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1160740007","content_text":"Summary\n\nThere is no such thing as eternal dominance, especially not in the innovation- and competition-driven tech sector.\nIn my view, Nvidia does not offer a good risk/reward ratio as an investment for the next five to ten years.\nAt its current price, the stock is overvalued for the next few years and offers nothing more than a massive downside potential of more than 50 percent.\n\nIntroduction\nNvidia's (NVDA) share price has followed a parabolic trend over the last few weeks, even in a logarithmic chart. In addition to the prolonged growth that accompanied the general optimistic stock market sentiment and the hype around tech stocks, we now see a short-term growth spurt. However, with the recent growth that has carried the company to a market cap of $760 billion, the stock has finally become a speculative bubble, joining all the other meme stocks. Thus, with Nvidia, I think we see how little an excellent business model has to do with an excellent investment. At its current price, the stock is overvalued for the next few years and offers nothing more than a massive downside potential of more than 50 percent.\nNothing but expectations\nRecently, hype sentiment has carried the share upwards. For this hype sentiment, theMetaverse/Omniverse, AI, and the Arm deal were the main reasons for exuberant optimism among Nvidia bulls.\nThe company created a lot of excitement around its appearance at the GTC conference and the introduction of the omniverse platform. With this platform, Nvidia wants to create virtual worldsin particular:\n\n Omniverse - a platform that serves as the connective tissue for physically accurate 3D virtual worlds - is gaining new features such as AR, VR and multi-GPU rendering, as well as integrations for infrastructure and industrial digital-twin applications with software from Bentley Systems and Esri.\n\n\n Omniverse enables engineers and designers to build physically accurate digital twins of buildings and products, or create massive, true-to-reality simulation environments for training robots or autonomous vehicles before they're deployed in the physical world.\n\nThe goal behind Omniverse is to create an ecosystem that is used by many industries worldwide. What is particularly exciting is that companies can create virtual twins of reality. The areas of application are manifold. For example, companies can test their products in this virtual world. It doesn't matter whether it's telecommunications companies that want to try the range of their transmission towers or data connection tools or car manufacturers that want to test the characteristics of cars in a real-life virtual environment. Instead of driving on a test track, the tests can take place in a virtual world. Awesome!\nWhat bugs me about this, however, are the many buzzwords. All these flowering words about quantum computers, AI, cyber security, etc., run through the entire (but otherwise fascinating and worth seeing) presentation. Of course, investors always need to clean up such presentations of all the advertising and touting to grasp the realistic opportunities. In the end, I think we are getting into the future that Nvidia is drawing for us. It may look different here and there, but the opportunities and monetization possibilities around virtual reality or virtual twins will be enormous and catapult us into the post-Internet age.\nBut that brings us to the point. You don't have to have owned Microsoft (MSFT) shares in 2000 to see the parallels. With Microsoft, as with many Internet stocks, there was great euphoria about the future of the Internet and the associated (disruptive)business opportunities:\n\n Before the dot.com or tech bubble burst, investors were convinced of the possibilities of the Internet, digitalization, and technical progress. Microsoft, it seemed, was the gatekeeper to this world with its Windows operating system and the Internet Explorer. The investors saw themselves at the beginning of a vast cycle. And Microsoft was able to keep its promises. By 1999, the company had increased its annual revenue by 30%. Besides, Microsoft was profitable even then and was able to increase its profits more than five-fold from 1995 to 2000.\n\n\n\n\n\nMicrosoft revenue & EPS from 1995-2001; taken from MSFT investor relation/graph by author\n\n\n But then, the bubble started to burst, and Judge Thomas Penfield Jacksondecidedthat Microsoft had violated the Sherman Antitrust Act due to abusive behavior, which only accelerated the bursting of the tech bubble. You know the rest of the story.\n\nAs with Microsoft in the dot.com bubble, the problem I see with Nvidia is that investors are euphorically betting on something that does not yet exist. So much of this future is currently priced into the share price without it even being clear what will end up in shareholders' pockets in the form of profits, cash flows, or dividends. Think of all the dot.com bubbles that burst even though companies like Cisco (CSCO) or Microsoft could deliver on their growth promises. Here we see the classic difference between companies and investments. An investment in a terrific company can still be a bad investment if the price is too high. If investors now buy Nvidia because of the Omniverse, it is nothing but a big gamble.\nAnd then, of course, there is Nvidia's classic business around the GPU and the Tegra processors. Here Nvidia is very successful. But this business is anything but a moat. Yes, Nvidia was able to increase sales and profits with it massively. The company has benefited primarily from the fact that the architecture of GPUs is superior to that of pure CPUs, such as those offered by Intel (INTC), for many applications such as high-performance computing, gaming, and servers.\nSource:Investor presentation\nNow Nvidia is looking to gain a foothold in the CPU market with the $40 billion Arm acquisition, using Arm's business model to secure the company's licenses. The Arm architecture is a key technology, especially for the entire smartphone industry. Arm is the architecture behind the SoCs used in virtually all smartphones and most tablet computers.\nBut it is not at all clear whether the deal will go through and at what price. Competition authorities such as the British CMA see considerable competition concerns and will presumably tie approval to significant concessions. Even if Nvidia does get clearance, the competition watchdogs will closely look at licensing practices. Unfortunately for Nvidia, and even though Arm does not make chips, the current chip shortage is prompting competition authorities to scrutinize the merger even more closely as the entire chip industry comes under scrutiny.\nIn short, the Arm deal may ultimately bring more advantages than disadvantages for Nvidia, but it is uncertain to what extent advance praise is justified here. Investors should not forget that the competition is not sleeping. Qualcomm, in particular, is very active right now and has made a significant strategic move with the NUVIA acquisition. I have already written about NUVIAhereandhere, which Qualcomm acquired for $1.4 billion:\n\n And then there's the startup NUVIA, which former Apple employees founded. CEO Amon wants to attack Apple's M1 processors with the acquired start-up and enter the laptop market next year. Qualcomm had previously tried integrating a smartphone SoC into a notebook with only minor modifications and okayish results.\n\n\n But now Qualcomm wants to release a Nuvia SoC based on ARM architecturenext year. This step would reduce Qualcomm's dependency on ARM and Nvidia enormously. Conversely, Qualcomm does not have much to lose since it can still license ARM technology from Nvidia in an emergency. The competition authorities will probably look particularly closely at the takeover of ARM by Nvidia to ensure that Nvidia does not put Qualcomm or other potential licensees at a disadvantage with too high license fees.\n\n\n The first comparisons of NUVIA's Phoenix chip to other chip suppliers already show a significant outperformance:\n\n\nSource:Nuvia Webpage\n\nMost recently, Qualcomm has been very optimistic about the prospects around the NUVIA deal:\n\n We are pleased with the strong market validation of Arm-based personal computing in the industry transition to a new SoC architecture. We're more confident than ever in the connected computing opportunity, our upcoming solutions powered by our NUVIA CPUs, and our collaboration with Microsoft. We're also seeing increased traction in consumer electronics.\n\nSo it is not that Nvidia will single-handedly dominate the Arm market. The competitive pressure is no less in the other business areas either. Above all, the eternal GPU competitor AMD (AMD) will continue to put pressure on the company. In autonomous driving, Intel is a heavyweight competitor alongside Tesla (TSLA), following its acquisition of the Israeli companyMobileye for over $15 billion in 2017.\nManaging expectations\nWith a P/E ratio of over 100, Nvidia would have to quadruple its profits to reach a valuation of 25, which is reasonable for a growth company. And admittedly, Nvidia has already achieved such growth.\nNevertheless, investors who invest in Nvidia now are speculating that Nvidia will increase its profits in the same way for the coming years. Of course, the company has already managed such developments in the past. In 2005, Nvidia was able to push its earnings per share from $0.05 to $0.33 within three years, which corresponds to a six-fold increase. But already in 2009 and 2010, Nvidia made losses. Only in 2017, it was it able to lift EPS above the 2008 level. Investors have to face it: profit increases are not a one-way street, especially not in the tech sector. And even analysts do not expect Nvidia to increase profits fast enough to reach reasonable valuation levels based on the current share price over the following years. In 2020, adjusted EPS was $2.50. Below you see expected earnings for the subsequent years, and you can also see that even the most optimistic analyst out of 19 surveyed does not expect Nvidia to achieve EPS higher than $7.25 in 2024.\nSource: www.dividendStocks.Cash\nSo we are far from saying that Nvidia will reach reasonable multiples in the next 4, 5, or 6 years based on today's share price. Even if we set the fair P/E multiple at 40. Considering the expected earnings, this results in an overvaluation of almost 30% even until 2024.\nSource: www.dividendStocks.Cash\nEven when looking at a DCF analysis, we see the apparent overvaluation and massive downside potential. Below you can see the expectations for the sales development until 2024.\n\nFor the DCF analysis, I even assume a much more optimistic scenario where the company will increase sales significantly higher. I also assume an improvement in margins.\nSource:alphaspread.com/estimates by author\nBased on these figures and assuming a discount rate of 9%, we see that Nvidia is overvalued by 50 percent, which is essentially in line with the fundamental valuation.\nSource: alphaspread.com/estimates by author\nInvestors should not forget that we could also see a change in interest rates next year. A discount rate of 9 percent could therefore be far too low. To remind you, the cost of equity was already 10 percent for Nvidia at the end of 2019. So what happens if we continue to take an optimistic growth scenario but increase the discount rate to 12 percent?\nSource:Discount rate history for Nvidia\nYou can see the result here: The Nvidia share would then be overvalued by almost 75 percent.\nSource: alphaspread.com/estimates by author\nConclusion\nThere is no such thing as eternal dominance, especially not in the innovation- and competition-driven tech sector. In my view, Nvidia does not offer a good risk/reward ratio as an investment for the next five to ten years. At its current price, the stock is overvalued for the next few years and offers nothing more than a massive downside potential of more than 50 percent.","news_type":1},"isVote":1,"tweetType":1,"viewCount":452,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":841543109,"gmtCreate":1635928603322,"gmtModify":1635928603322,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"To the moon!!&nbsp;","listText":"To the moon!!&nbsp;","text":"To the moon!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/841543109","repostId":"1178338626","repostType":4,"isVote":1,"tweetType":1,"viewCount":427,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":843581898,"gmtCreate":1635841643487,"gmtModify":1635841646978,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Go go go!!!&nbsp;","listText":"Go go go!!!&nbsp;","text":"Go go go!!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/843581898","repostId":"1146954113","repostType":2,"repost":{"id":"1146954113","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635841327,"share":"https://www.laohu8.com/m/news/1146954113?lang=&edition=full","pubTime":"2021-11-02 16:22","market":"us","language":"en","title":"Novavax shares jumped another 4.4% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1146954113","media":"Tiger Newspress","summary":"Novavax shares jumped another 4.4% in premarket trading Tuesday after rising nearly 16% yesterday as","content":"<p>Novavax shares jumped another 4.4% in premarket trading&nbsp;Tuesday&nbsp;after rising nearly 16% yesterday&nbsp;as&nbsp;Novavax COVID-19 vaccine got first authorization; expected more within weeks.</p>\n<p><img src=\"https://static.tigerbbs.com/93777ff8ed669db1e3ea1516ae6b0f1f\" tg-width=\"849\" tg-height=\"617\" referrerpolicy=\"no-referrer\"></p>\n<p>Novavax Inc expects regulators in India, the Philippines and elsewhere to make a decision on its COVID-19 vaccine within “weeks,” its chief executive told Reuters, after the shot on Monday received its first emergency use authorization (EUA) from Indonesia.</p>\n<p>The company also said it had filed an application for emergency use of the vaccine to Canada and the European Medicines Agency.</p>\n<p>For Indonesia, the shot will be manufactured by the world’s largest vaccine manufacturer, Serum Institute in India (SII), and sold under the Indian company’s brand name, Covovax. Novavax said initial shipments into Indonesia are expected to begin imminently.</p>\n<p>The World Health Organization (WHO) is also reviewing Novavax’s regulatory filing and the U.S. drugmaker expects that review to be resolved in the coming weeks, Chief Executive Stanley Erck told Reuters in a phone interview on Monday.</p>\n<p>A green light from the WHO would set the stage for Novavax to begin shipping doses to the COVAX program that supplies shots to low-income countries. Novavax and SII have together committed to provide more than 1.1 billion doses to COVAX, which is co-led by the WHO.</p>\n<p>“I think we’ll get some doses to COVAX this year,” Erck said. “But I think (Novavax is) going to really start being able to ship large quantity to COVAX in the first quarter” of 2022.</p>\n<p>Erck said Novavax has resolved all of its manufacturing challenges and does not expect regulators to have any further concerns about its production processes.</p>\n<p>He said Novavax is “in dialogue with the U.S. FDA and ... we expect a full submission within the next several weeks.”</p>\n<p>Novavax had delayed filing for U.S. approval, and Politico reported last month that the company faced production and quality problems.</p>\n<p>SII is authorized to make the Novavax vaccine and the U.S. company said it will apply for regulatory authorization for other facilities, such as its plant in the Czech republic, in the coming weeks.</p>\n<p>Indonesia is slated to receive 20 million doses of the protein-based vaccine this year, according to the government.</p>\n<p>Penny Lukito, chief of the National Agency for Drug and Food Control of Indonesia, did not immediately respond to a Reuters request for comment.</p>\n<p>Novavax has so far applied for EUA in various countries, including the UK, Australia, India and the Philippines.</p>\n<p>“It will be weeks, not months, for them to review” Novavax’s regulatory submissions and potentially clear the shot for use, Erck said.</p>\n<p>The company, along with Japanese partner Takeda Pharmaceutical Co, said on Friday it was preparing to seek regulatory approval for a rollout in Japan early next year.</p>\n<p>The Novavax shot was shown to be more than 90% effective, including against a variety of concerning variants of the coronavirus in a large, late-stage U.S.-based trial.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax shares jumped another 4.4% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax shares jumped another 4.4% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-02 16:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Novavax shares jumped another 4.4% in premarket trading&nbsp;Tuesday&nbsp;after rising nearly 16% yesterday&nbsp;as&nbsp;Novavax COVID-19 vaccine got first authorization; expected more within weeks.</p>\n<p><img src=\"https://static.tigerbbs.com/93777ff8ed669db1e3ea1516ae6b0f1f\" tg-width=\"849\" tg-height=\"617\" referrerpolicy=\"no-referrer\"></p>\n<p>Novavax Inc expects regulators in India, the Philippines and elsewhere to make a decision on its COVID-19 vaccine within “weeks,” its chief executive told Reuters, after the shot on Monday received its first emergency use authorization (EUA) from Indonesia.</p>\n<p>The company also said it had filed an application for emergency use of the vaccine to Canada and the European Medicines Agency.</p>\n<p>For Indonesia, the shot will be manufactured by the world’s largest vaccine manufacturer, Serum Institute in India (SII), and sold under the Indian company’s brand name, Covovax. Novavax said initial shipments into Indonesia are expected to begin imminently.</p>\n<p>The World Health Organization (WHO) is also reviewing Novavax’s regulatory filing and the U.S. drugmaker expects that review to be resolved in the coming weeks, Chief Executive Stanley Erck told Reuters in a phone interview on Monday.</p>\n<p>A green light from the WHO would set the stage for Novavax to begin shipping doses to the COVAX program that supplies shots to low-income countries. Novavax and SII have together committed to provide more than 1.1 billion doses to COVAX, which is co-led by the WHO.</p>\n<p>“I think we’ll get some doses to COVAX this year,” Erck said. “But I think (Novavax is) going to really start being able to ship large quantity to COVAX in the first quarter” of 2022.</p>\n<p>Erck said Novavax has resolved all of its manufacturing challenges and does not expect regulators to have any further concerns about its production processes.</p>\n<p>He said Novavax is “in dialogue with the U.S. FDA and ... we expect a full submission within the next several weeks.”</p>\n<p>Novavax had delayed filing for U.S. approval, and Politico reported last month that the company faced production and quality problems.</p>\n<p>SII is authorized to make the Novavax vaccine and the U.S. company said it will apply for regulatory authorization for other facilities, such as its plant in the Czech republic, in the coming weeks.</p>\n<p>Indonesia is slated to receive 20 million doses of the protein-based vaccine this year, according to the government.</p>\n<p>Penny Lukito, chief of the National Agency for Drug and Food Control of Indonesia, did not immediately respond to a Reuters request for comment.</p>\n<p>Novavax has so far applied for EUA in various countries, including the UK, Australia, India and the Philippines.</p>\n<p>“It will be weeks, not months, for them to review” Novavax’s regulatory submissions and potentially clear the shot for use, Erck said.</p>\n<p>The company, along with Japanese partner Takeda Pharmaceutical Co, said on Friday it was preparing to seek regulatory approval for a rollout in Japan early next year.</p>\n<p>The Novavax shot was shown to be more than 90% effective, including against a variety of concerning variants of the coronavirus in a large, late-stage U.S.-based trial.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1146954113","content_text":"Novavax shares jumped another 4.4% in premarket trading Tuesday after rising nearly 16% yesterday as Novavax COVID-19 vaccine got first authorization; expected more within weeks.\n\nNovavax Inc expects regulators in India, the Philippines and elsewhere to make a decision on its COVID-19 vaccine within “weeks,” its chief executive told Reuters, after the shot on Monday received its first emergency use authorization (EUA) from Indonesia.\nThe company also said it had filed an application for emergency use of the vaccine to Canada and the European Medicines Agency.\nFor Indonesia, the shot will be manufactured by the world’s largest vaccine manufacturer, Serum Institute in India (SII), and sold under the Indian company’s brand name, Covovax. Novavax said initial shipments into Indonesia are expected to begin imminently.\nThe World Health Organization (WHO) is also reviewing Novavax’s regulatory filing and the U.S. drugmaker expects that review to be resolved in the coming weeks, Chief Executive Stanley Erck told Reuters in a phone interview on Monday.\nA green light from the WHO would set the stage for Novavax to begin shipping doses to the COVAX program that supplies shots to low-income countries. Novavax and SII have together committed to provide more than 1.1 billion doses to COVAX, which is co-led by the WHO.\n“I think we’ll get some doses to COVAX this year,” Erck said. “But I think (Novavax is) going to really start being able to ship large quantity to COVAX in the first quarter” of 2022.\nErck said Novavax has resolved all of its manufacturing challenges and does not expect regulators to have any further concerns about its production processes.\nHe said Novavax is “in dialogue with the U.S. FDA and ... we expect a full submission within the next several weeks.”\nNovavax had delayed filing for U.S. approval, and Politico reported last month that the company faced production and quality problems.\nSII is authorized to make the Novavax vaccine and the U.S. company said it will apply for regulatory authorization for other facilities, such as its plant in the Czech republic, in the coming weeks.\nIndonesia is slated to receive 20 million doses of the protein-based vaccine this year, according to the government.\nPenny Lukito, chief of the National Agency for Drug and Food Control of Indonesia, did not immediately respond to a Reuters request for comment.\nNovavax has so far applied for EUA in various countries, including the UK, Australia, India and the Philippines.\n“It will be weeks, not months, for them to review” Novavax’s regulatory submissions and potentially clear the shot for use, Erck said.\nThe company, along with Japanese partner Takeda Pharmaceutical Co, said on Friday it was preparing to seek regulatory approval for a rollout in Japan early next year.\nThe Novavax shot was shown to be more than 90% effective, including against a variety of concerning variants of the coronavirus in a large, late-stage U.S.-based trial.","news_type":1},"isVote":1,"tweetType":1,"viewCount":402,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":851838102,"gmtCreate":1634890474595,"gmtModify":1634890474595,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AMD\">$AMD(AMD)$</a>&nbsp;up up up!!!&nbsp;","listText":"<a href=\"https://laohu8.com/S/AMD\">$AMD(AMD)$</a>&nbsp;up up up!!!&nbsp;","text":"$AMD(AMD)$ up up up!!!","images":[{"img":"https://static.tigerbbs.com/2da1478496dda3d23161f71934bb6c2b","width":"1080","height":"2375"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/851838102","isVote":1,"tweetType":1,"viewCount":504,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":859499264,"gmtCreate":1634718770094,"gmtModify":1634721067878,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Gg&nbsp;overpromise again","listText":"Gg&nbsp;overpromise again","text":"Gg overpromise again","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/859499264","repostId":"1174375951","repostType":2,"isVote":1,"tweetType":1,"viewCount":551,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":850281587,"gmtCreate":1634602242348,"gmtModify":1634602242420,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Very good","listText":"Very good","text":"Very good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/850281587","repostId":"1114416896","repostType":4,"isVote":1,"tweetType":1,"viewCount":519,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":829410404,"gmtCreate":1633532533184,"gmtModify":1633532533259,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"But why stock price still drop??&nbsp;","listText":"But why stock price still drop??&nbsp;","text":"But why stock price still drop??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/829410404","repostId":"1169679917","repostType":2,"isVote":1,"tweetType":1,"viewCount":637,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":829404697,"gmtCreate":1633530962458,"gmtModify":1633530962530,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"why sell???","listText":"why sell???","text":"why sell???","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/829404697","repostId":"1126696993","repostType":2,"repost":{"id":"1126696993","pubTimestamp":1633523514,"share":"https://www.laohu8.com/m/news/1126696993?lang=&edition=full","pubTime":"2021-10-06 20:31","market":"us","language":"en","title":"Novavax CEO Stanley Erck sells ~92K shares as part of trading plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1126696993","media":"seekingalpha","summary":"Novavax CEO Stanley Erck has exercised a pre-agreed trading plan and sold 91,829 shares.\nHe sold 42,","content":"<p>Novavax&nbsp;CEO Stanley Erck has exercised a pre-agreed trading plan and sold 91,829 shares.</p>\n<p>He sold 42,829 shares at a price of $176.15 for ~$7.5M. In thesame filing, he acquired 42,829 shares at a strike of $27.45</p>\n<p>Inanother filing, Erck sold 49K shares at a price of $175.10 for ~$8.6M. He also acquired 49K shares at a strike of $27.17.</p>\n<p>Last month, Novavax director David Mottsold a large number of shares.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax CEO Stanley Erck sells ~92K shares as part of trading plan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax CEO Stanley Erck sells ~92K shares as part of trading plan\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-06 20:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3749771-novavax-ceo-stanley-erck-sells-92k-shares-as-part-of-trading-plan><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novavax CEO Stanley Erck has exercised a pre-agreed trading plan and sold 91,829 shares.\nHe sold 42,829 shares at a price of $176.15 for ~$7.5M. In thesame filing, he acquired 42,829 shares at a ...</p>\n\n<a href=\"https://seekingalpha.com/news/3749771-novavax-ceo-stanley-erck-sells-92k-shares-as-part-of-trading-plan\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://seekingalpha.com/news/3749771-novavax-ceo-stanley-erck-sells-92k-shares-as-part-of-trading-plan","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1126696993","content_text":"Novavax CEO Stanley Erck has exercised a pre-agreed trading plan and sold 91,829 shares.\nHe sold 42,829 shares at a price of $176.15 for ~$7.5M. In thesame filing, he acquired 42,829 shares at a strike of $27.45\nInanother filing, Erck sold 49K shares at a price of $175.10 for ~$8.6M. He also acquired 49K shares at a strike of $27.17.\nLast month, Novavax director David Mottsold a large number of shares.","news_type":1},"isVote":1,"tweetType":1,"viewCount":578,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":871185699,"gmtCreate":1637037132655,"gmtModify":1637037302349,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Pls drop so that i can buy more","listText":"Pls drop so that i can buy more","text":"Pls drop so that i can buy more","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/871185699","repostId":"1160740007","repostType":4,"isVote":1,"tweetType":1,"viewCount":452,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":843581898,"gmtCreate":1635841643487,"gmtModify":1635841646978,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Go go go!!!&nbsp;","listText":"Go go go!!!&nbsp;","text":"Go go go!!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/843581898","repostId":"1146954113","repostType":2,"isVote":1,"tweetType":1,"viewCount":402,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":841543109,"gmtCreate":1635928603322,"gmtModify":1635928603322,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"To the moon!!&nbsp;","listText":"To the moon!!&nbsp;","text":"To the moon!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/841543109","repostId":"1178338626","repostType":4,"repost":{"id":"1178338626","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635928227,"share":"https://www.laohu8.com/m/news/1178338626?lang=&edition=full","pubTime":"2021-11-03 16:30","market":"us","language":"en","title":"Some meme stocks skyrocketed in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1178338626","media":"Tiger Newspress","summary":"Some meme stocks skyrocketed in premarket trading.Bed Bath & Beyond,R.R. Donnelley & Sons,Naked Bran","content":"<p>Some meme stocks skyrocketed in premarket trading.Bed Bath &amp; Beyond,R.R. Donnelley &amp; Sons,Naked Brand,Koss,Express,AMC,GameStop&nbsp;and&nbsp;BlackBerry&nbsp;soared between 4% and 62%.</p>\n<p><img src=\"https://static.tigerbbs.com/b016995062645d8011221cff13a86966\" tg-width=\"404\" tg-height=\"486\" referrerpolicy=\"no-referrer\"></p>\n<p><a href=\"https://laohu8.com/NW/1113177921\" target=\"_blank\">Bed Bath &amp; Beyond</a>,the home-goods retailer announced news that likely fueled a so-called short squeeze, where hedge funds that had bet against the stock were forced to buy back their shares to cut losses.</p>\n<p>Commercial-printing company&nbsp;R.R. Donnelley &amp; Sons&nbsp;Co.&nbsp;is nearing a deal to sell itself to a private-equity firm for just over $2 billion including debt, according to people familiar with the matter.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Some meme stocks skyrocketed in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSome meme stocks skyrocketed in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-03 16:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Some meme stocks skyrocketed in premarket trading.Bed Bath &amp; Beyond,R.R. Donnelley &amp; Sons,Naked Brand,Koss,Express,AMC,GameStop&nbsp;and&nbsp;BlackBerry&nbsp;soared between 4% and 62%.</p>\n<p><img src=\"https://static.tigerbbs.com/b016995062645d8011221cff13a86966\" tg-width=\"404\" tg-height=\"486\" referrerpolicy=\"no-referrer\"></p>\n<p><a href=\"https://laohu8.com/NW/1113177921\" target=\"_blank\">Bed Bath &amp; Beyond</a>,the home-goods retailer announced news that likely fueled a so-called short squeeze, where hedge funds that had bet against the stock were forced to buy back their shares to cut losses.</p>\n<p>Commercial-printing company&nbsp;R.R. Donnelley &amp; Sons&nbsp;Co.&nbsp;is nearing a deal to sell itself to a private-equity firm for just over $2 billion including debt, according to people familiar with the matter.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"KOSS":"高斯电子","BBBY":"3B家居","BB":"黑莓","RRD":"当纳利","GME":"游戏驿站","EXPR":"Express, Inc.","AMC":"AMC院线"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1178338626","content_text":"Some meme stocks skyrocketed in premarket trading.Bed Bath & Beyond,R.R. Donnelley & Sons,Naked Brand,Koss,Express,AMC,GameStop and BlackBerry soared between 4% and 62%.\n\nBed Bath & Beyond,the home-goods retailer announced news that likely fueled a so-called short squeeze, where hedge funds that had bet against the stock were forced to buy back their shares to cut losses.\nCommercial-printing company R.R. Donnelley & Sons Co. is nearing a deal to sell itself to a private-equity firm for just over $2 billion including debt, according to people familiar with the matter.","news_type":1},"isVote":1,"tweetType":1,"viewCount":427,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":859499264,"gmtCreate":1634718770094,"gmtModify":1634721067878,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Gg&nbsp;overpromise again","listText":"Gg&nbsp;overpromise again","text":"Gg overpromise again","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/859499264","repostId":"1174375951","repostType":2,"repost":{"id":"1174375951","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1634717661,"share":"https://www.laohu8.com/m/news/1174375951?lang=&edition=full","pubTime":"2021-10-20 16:14","market":"us","language":"en","title":"Novavax plunged over 20% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1174375951","media":"Tiger Newspress","summary":"(Oct 20)  Novavax may delay the delivery of 1 billion doses of coronavirus vaccine because of the pr","content":"<p>(Oct 20)&nbsp; <a href=\"https://laohu8.com/S/NVAX\">Novavax</a>&nbsp;may delay the delivery of 1 billion doses of coronavirus vaccine because of the production problems.</p>\n<p><img src=\"https://static.tigerbbs.com/f3995877f1c786d310a457ababf9ee9e\" tg-width=\"1043\" tg-height=\"564\" referrerpolicy=\"no-referrer\">The world’s vaccine distributor has been counting on U.S. companies to provide more than 2 billion doses to lower and middle-income countries by the end of 2022 — a crucial step in ending the Covid-19 pandemic.</p>\n<p>But the campaign run by the international consortium known as COVAX, which has already been delayed significantly because of production lags, is now likely to fall short by more than 1 billion doses as a key supplier faces significant hurdles in proving it can manufacture a shot that meets regulators’ quality standards, according to three people with direct knowledge of the company’s problems.</p>\n<p>The delay, which was confirmed by three other people familiar with the discussions between Maryland-based Novavax and the Biden administration, represents a major setback in the effort to vaccinate the world in the wake of new, more transmissible variants.</p>\n<p>The U.S. government invested $1.6 billion in Novavax in 2020 — the most it devoted to any vaccine maker at the time — in hopes that it would offer the world another option for a safe and effective vaccine to help protect against Covid-19. But the company has consistently run into production problems. The methods it used to test the purity of the vaccine have fallen short of regulators’ standards and the company has not been able to prove that it can produce a shot that is consistently up to snuff, according to multiple people familiar with Novavax’s difficulties. All spoke on the condition of anonymity to discuss sensitive company conversations.</p>\n<p>Although Novavax recently attested to some of its analytics and testing issues in aquarterly filing with the Securities and Exchange Commission, the company’s issues are more concerning than previously understood, according to two of the people with direct knowledge of the matter.</p>\n<p>The Food and Drug Administration works out purity levels with each manufacturer according to June 2020 guidance for coronavirus vaccines, but it is generally understood that each vaccine batch should reach at least 90 percent. The company has struggled to attain anywhere close to that, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the people with direct knowledge of the situation said. Another person familiar with the company’s manufacturing process said Novavax has recently shown purity levels hovering around 70 percent. Low purity levels increase the chance that contaminants or unnecessary substances are in the final product, rendering the vaccine less effective or introducing the chance that patients could react to unknown ingredients.</p>\n<p>COVAX, which recently downgraded its 2021 goal from 2 billion to 1.425 billion doses, has already estimated that it faces a supply shortfall of as many as 1 billion doses in its effort to vaccinate the developing world. If Novavax falters, it could double the deficit through 2022, leaving hundreds of millions of people without immunity against Covid-19 and extending the pandemic.</p>\n<p>“COVAX continues to be challenged for adequate supply … in that context, Novavax’s manufacturing challenges and delays have been massively disruptive,” said Krishna Udayakumar, director of the <a href=\"https://laohu8.com/S/DRE\">Duke</a> Global Health Innovation Center.</p>\n<p>The global coalition is already behind on hundreds of millions of planned doses this month, having shipped just 371 million of its 700 million dose target for October. It is now also at risk of missing its already downgraded 2021 target.</p>\n<p>Between Novavax and other manufacturers’ hurdles, “COVAX has had to scramble to revise its supply strategy significantly in real time,” Udayakumar said. As a result, global health groups are emphasizing more donations to cover immediate needs, he added.</p>\n<p>In a statement, Novavax Senior Vice President of Investor Relations and Corporate Affairs Silvia Taylor told POLITICO that the company’s analytical testing methods have been “validated” — but did not answer questions about whether the FDA had signed off on them. The company still plans on filing an emergency use authorization by the end of the year, Taylor said.</p>\n<p>“The vaccine development and regulatory submission processes are highly complex and often require years to advance to the point where we are now. We will fulfill all of our committed doses both in the US and globally,” Taylor said.</p>\n<p>The White House and the Department of Health and Human Services did not respond to multiple requests for comment.</p>\n<p>But three people familiar with the matter said they are not confident that the company has the resources needed to reproduce a high-quality vaccine on a consistent basis — a benchmark Novavax must meet before that time. Those same people said Novavax could potentially fix its manufacturing issues and reach full licensure by the end of 2022.</p>\n<p>Novavax — which has never produced a vaccine before — declined to answer specific questions about its product’s purity levels and whether it had been successful in addressing its longstanding manufacturing issues.</p>\n<p>Unlike <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and Moderna, the first manufacturers to launch vaccines using rapidly produced messenger RNA, Novavax is employing the previously used but complicated approach of creating the key ingredient with bug cells. While the process, which involves infecting the cells to produce spike proteins, is familiar to scientists, it is difficult to scale.</p>\n<p>The revelations about Novavax’s continued manufacturing problems come at a time when only 36 percent of the world is vaccinated and as leaders of developing nations continue to pressure the U.S. to deliver more doses. In Africa alone, only 4.4 percent of the population is vaccinated.</p>\n<p>That includes some of the continent’s most populous nations, like Nigeria and Uganda, where about 1 percent of citizens are fully vaccinated.</p>\n<p>Novavax is just the latest vaccine maker to run into core production problems after promising to serve as a major vaccine contributor to the developing world. In April, Johnson &amp; Johnsonhalted work at a Baltimore facilityrun by contract manufacturer <a href=\"https://laohu8.com/S/EBS\">Emergent BioSolutions</a> after it found that 15 million doses had been accidentally contaminated with ingredients from a separate Covid-19 vaccine.</p>\n<p>J&amp;J’s manufacturing process has been slow to recover, and to date it has produced just a fraction of the 200 million shots it initially pledged to COVAX by the end of the year, according to records kept by UNICEF.</p>\n<p>“Overpromising and underdelivering is the name of the game for these manufacturers,” said Asia Russell, executive director of international advocacy group Health GAP. “And that’s the infrastructure of the global response, which is terrifying.”</p>\n<p>Unlike Johnson &amp; Johnson, Novavax is a novice in the vaccine world. It has never successfully launched a vaccine, and had struggled financially prior to the pandemic. After a string of drug development failures, it sold its manufacturing facilities in 2019 — a deal that also included parting with 100 employees. In May of that year, Novavax’s stock price dropped as low as 36 cents per share.</p>\n<p>Yet the company’s fortunes shifted as Covid-19 took hold. Amid a scramble early in the pandemic to develop a range of vaccine candidates, the Trump administration awarded Novavax $1.6 billion to aid work on its Covid-19 shot — the largest deal given to any Covid-19 vaccine maker at that time.</p>\n<p>The contract represented a major vote of confidence in Novavax’s capabilities — and a bet that appeared to pay off after late-stage trials showed the vaccine was 90 percent effective against the virus.</p>\n<p>But even then, senior Trump administration officials on Operation Warp Speed — a group tasked with accelerating vaccine development — repeatedly warned the company that it risked running into problems in scaling up manufacturing of the shot, two people with direct knowledge of those discussions said.</p>\n<p>In particular, they worried that Novavax would have difficulty ensuring that the vaccine consistently met the FDA’s rigorous quality standards once the vaccine went into mass production — the exact problem that has now stymied the company for months.</p>\n<p>“They rushed the process,” one of the people with knowledge of the matter said. “It’s hard to make. And they can’t make it.”</p>\n<p>Taylor, the Novavax spokesperson, said in a statement that it has incorporated feedback from regulators and has made “tremendous progress with the scale-up of our commercial manufacturing processes.” The company is still on track to produce 150 million doses a month by the end of the year, she said, and has stockpiled tens of millions of doses ahead of regulatory filings in the U.S. and internationally.</p>\n<p>Company executives in recent presentations to investors have struck a similarly optimistic tone, downplaying the manufacturing snags and predicting it will soon be cleared to begin distributing doses. During aSept. 29 investor event, Chief Commercial Officer John Trizzino said the company had “resolved” its problems and was close to submitting a final regulatory application.</p>\n<p>“We’re really moving along with testing our lots now,” added Gregory Glenn, president of Novavax’s research and development, referring to batches of its vaccine. “We think that this is shortly going to come to a close.”</p>\n<p>U.S. officials working with the company are not as confident, according to three people with knowledge of the matter. Novavax’s manufacturing problems are seen as far more difficult to fix than the sanitary and design concerns that halted production of J&amp;J’s vaccine at the Emergent plant earlier this year, those people said.</p>\n<p>And even as the company begins to seek regulatory approval in other countries, there remains doubt in the U.S. that it has solved the fundamental vaccine purity flaws that the people with knowledge said have affected its ability to make doses at plants around the world.</p>\n<p>Several vaccine batches have already been discarded, and four people with knowledge of the matter say U.S. officials now no longer expect the company to win FDA sign-off on the vaccine until next year at the earliest.</p>\n<p>“At some level, I think the efficacy was never going to outweigh the risk associated with the impurity that was in there,” said one of the people with knowledge of the matter. “I’m not surprised this is where we are.”</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax plunged over 20% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax plunged over 20% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-20 16:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(Oct 20)&nbsp; <a href=\"https://laohu8.com/S/NVAX\">Novavax</a>&nbsp;may delay the delivery of 1 billion doses of coronavirus vaccine because of the production problems.</p>\n<p><img src=\"https://static.tigerbbs.com/f3995877f1c786d310a457ababf9ee9e\" tg-width=\"1043\" tg-height=\"564\" referrerpolicy=\"no-referrer\">The world’s vaccine distributor has been counting on U.S. companies to provide more than 2 billion doses to lower and middle-income countries by the end of 2022 — a crucial step in ending the Covid-19 pandemic.</p>\n<p>But the campaign run by the international consortium known as COVAX, which has already been delayed significantly because of production lags, is now likely to fall short by more than 1 billion doses as a key supplier faces significant hurdles in proving it can manufacture a shot that meets regulators’ quality standards, according to three people with direct knowledge of the company’s problems.</p>\n<p>The delay, which was confirmed by three other people familiar with the discussions between Maryland-based Novavax and the Biden administration, represents a major setback in the effort to vaccinate the world in the wake of new, more transmissible variants.</p>\n<p>The U.S. government invested $1.6 billion in Novavax in 2020 — the most it devoted to any vaccine maker at the time — in hopes that it would offer the world another option for a safe and effective vaccine to help protect against Covid-19. But the company has consistently run into production problems. The methods it used to test the purity of the vaccine have fallen short of regulators’ standards and the company has not been able to prove that it can produce a shot that is consistently up to snuff, according to multiple people familiar with Novavax’s difficulties. All spoke on the condition of anonymity to discuss sensitive company conversations.</p>\n<p>Although Novavax recently attested to some of its analytics and testing issues in aquarterly filing with the Securities and Exchange Commission, the company’s issues are more concerning than previously understood, according to two of the people with direct knowledge of the matter.</p>\n<p>The Food and Drug Administration works out purity levels with each manufacturer according to June 2020 guidance for coronavirus vaccines, but it is generally understood that each vaccine batch should reach at least 90 percent. The company has struggled to attain anywhere close to that, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the people with direct knowledge of the situation said. Another person familiar with the company’s manufacturing process said Novavax has recently shown purity levels hovering around 70 percent. Low purity levels increase the chance that contaminants or unnecessary substances are in the final product, rendering the vaccine less effective or introducing the chance that patients could react to unknown ingredients.</p>\n<p>COVAX, which recently downgraded its 2021 goal from 2 billion to 1.425 billion doses, has already estimated that it faces a supply shortfall of as many as 1 billion doses in its effort to vaccinate the developing world. If Novavax falters, it could double the deficit through 2022, leaving hundreds of millions of people without immunity against Covid-19 and extending the pandemic.</p>\n<p>“COVAX continues to be challenged for adequate supply … in that context, Novavax’s manufacturing challenges and delays have been massively disruptive,” said Krishna Udayakumar, director of the <a href=\"https://laohu8.com/S/DRE\">Duke</a> Global Health Innovation Center.</p>\n<p>The global coalition is already behind on hundreds of millions of planned doses this month, having shipped just 371 million of its 700 million dose target for October. It is now also at risk of missing its already downgraded 2021 target.</p>\n<p>Between Novavax and other manufacturers’ hurdles, “COVAX has had to scramble to revise its supply strategy significantly in real time,” Udayakumar said. As a result, global health groups are emphasizing more donations to cover immediate needs, he added.</p>\n<p>In a statement, Novavax Senior Vice President of Investor Relations and Corporate Affairs Silvia Taylor told POLITICO that the company’s analytical testing methods have been “validated” — but did not answer questions about whether the FDA had signed off on them. The company still plans on filing an emergency use authorization by the end of the year, Taylor said.</p>\n<p>“The vaccine development and regulatory submission processes are highly complex and often require years to advance to the point where we are now. We will fulfill all of our committed doses both in the US and globally,” Taylor said.</p>\n<p>The White House and the Department of Health and Human Services did not respond to multiple requests for comment.</p>\n<p>But three people familiar with the matter said they are not confident that the company has the resources needed to reproduce a high-quality vaccine on a consistent basis — a benchmark Novavax must meet before that time. Those same people said Novavax could potentially fix its manufacturing issues and reach full licensure by the end of 2022.</p>\n<p>Novavax — which has never produced a vaccine before — declined to answer specific questions about its product’s purity levels and whether it had been successful in addressing its longstanding manufacturing issues.</p>\n<p>Unlike <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and Moderna, the first manufacturers to launch vaccines using rapidly produced messenger RNA, Novavax is employing the previously used but complicated approach of creating the key ingredient with bug cells. While the process, which involves infecting the cells to produce spike proteins, is familiar to scientists, it is difficult to scale.</p>\n<p>The revelations about Novavax’s continued manufacturing problems come at a time when only 36 percent of the world is vaccinated and as leaders of developing nations continue to pressure the U.S. to deliver more doses. In Africa alone, only 4.4 percent of the population is vaccinated.</p>\n<p>That includes some of the continent’s most populous nations, like Nigeria and Uganda, where about 1 percent of citizens are fully vaccinated.</p>\n<p>Novavax is just the latest vaccine maker to run into core production problems after promising to serve as a major vaccine contributor to the developing world. In April, Johnson &amp; Johnsonhalted work at a Baltimore facilityrun by contract manufacturer <a href=\"https://laohu8.com/S/EBS\">Emergent BioSolutions</a> after it found that 15 million doses had been accidentally contaminated with ingredients from a separate Covid-19 vaccine.</p>\n<p>J&amp;J’s manufacturing process has been slow to recover, and to date it has produced just a fraction of the 200 million shots it initially pledged to COVAX by the end of the year, according to records kept by UNICEF.</p>\n<p>“Overpromising and underdelivering is the name of the game for these manufacturers,” said Asia Russell, executive director of international advocacy group Health GAP. “And that’s the infrastructure of the global response, which is terrifying.”</p>\n<p>Unlike Johnson &amp; Johnson, Novavax is a novice in the vaccine world. It has never successfully launched a vaccine, and had struggled financially prior to the pandemic. After a string of drug development failures, it sold its manufacturing facilities in 2019 — a deal that also included parting with 100 employees. In May of that year, Novavax’s stock price dropped as low as 36 cents per share.</p>\n<p>Yet the company’s fortunes shifted as Covid-19 took hold. Amid a scramble early in the pandemic to develop a range of vaccine candidates, the Trump administration awarded Novavax $1.6 billion to aid work on its Covid-19 shot — the largest deal given to any Covid-19 vaccine maker at that time.</p>\n<p>The contract represented a major vote of confidence in Novavax’s capabilities — and a bet that appeared to pay off after late-stage trials showed the vaccine was 90 percent effective against the virus.</p>\n<p>But even then, senior Trump administration officials on Operation Warp Speed — a group tasked with accelerating vaccine development — repeatedly warned the company that it risked running into problems in scaling up manufacturing of the shot, two people with direct knowledge of those discussions said.</p>\n<p>In particular, they worried that Novavax would have difficulty ensuring that the vaccine consistently met the FDA’s rigorous quality standards once the vaccine went into mass production — the exact problem that has now stymied the company for months.</p>\n<p>“They rushed the process,” one of the people with knowledge of the matter said. “It’s hard to make. And they can’t make it.”</p>\n<p>Taylor, the Novavax spokesperson, said in a statement that it has incorporated feedback from regulators and has made “tremendous progress with the scale-up of our commercial manufacturing processes.” The company is still on track to produce 150 million doses a month by the end of the year, she said, and has stockpiled tens of millions of doses ahead of regulatory filings in the U.S. and internationally.</p>\n<p>Company executives in recent presentations to investors have struck a similarly optimistic tone, downplaying the manufacturing snags and predicting it will soon be cleared to begin distributing doses. During aSept. 29 investor event, Chief Commercial Officer John Trizzino said the company had “resolved” its problems and was close to submitting a final regulatory application.</p>\n<p>“We’re really moving along with testing our lots now,” added Gregory Glenn, president of Novavax’s research and development, referring to batches of its vaccine. “We think that this is shortly going to come to a close.”</p>\n<p>U.S. officials working with the company are not as confident, according to three people with knowledge of the matter. Novavax’s manufacturing problems are seen as far more difficult to fix than the sanitary and design concerns that halted production of J&amp;J’s vaccine at the Emergent plant earlier this year, those people said.</p>\n<p>And even as the company begins to seek regulatory approval in other countries, there remains doubt in the U.S. that it has solved the fundamental vaccine purity flaws that the people with knowledge said have affected its ability to make doses at plants around the world.</p>\n<p>Several vaccine batches have already been discarded, and four people with knowledge of the matter say U.S. officials now no longer expect the company to win FDA sign-off on the vaccine until next year at the earliest.</p>\n<p>“At some level, I think the efficacy was never going to outweigh the risk associated with the impurity that was in there,” said one of the people with knowledge of the matter. “I’m not surprised this is where we are.”</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174375951","content_text":"(Oct 20)  Novavax may delay the delivery of 1 billion doses of coronavirus vaccine because of the production problems.\nThe world’s vaccine distributor has been counting on U.S. companies to provide more than 2 billion doses to lower and middle-income countries by the end of 2022 — a crucial step in ending the Covid-19 pandemic.\nBut the campaign run by the international consortium known as COVAX, which has already been delayed significantly because of production lags, is now likely to fall short by more than 1 billion doses as a key supplier faces significant hurdles in proving it can manufacture a shot that meets regulators’ quality standards, according to three people with direct knowledge of the company’s problems.\nThe delay, which was confirmed by three other people familiar with the discussions between Maryland-based Novavax and the Biden administration, represents a major setback in the effort to vaccinate the world in the wake of new, more transmissible variants.\nThe U.S. government invested $1.6 billion in Novavax in 2020 — the most it devoted to any vaccine maker at the time — in hopes that it would offer the world another option for a safe and effective vaccine to help protect against Covid-19. But the company has consistently run into production problems. The methods it used to test the purity of the vaccine have fallen short of regulators’ standards and the company has not been able to prove that it can produce a shot that is consistently up to snuff, according to multiple people familiar with Novavax’s difficulties. All spoke on the condition of anonymity to discuss sensitive company conversations.\nAlthough Novavax recently attested to some of its analytics and testing issues in aquarterly filing with the Securities and Exchange Commission, the company’s issues are more concerning than previously understood, according to two of the people with direct knowledge of the matter.\nThe Food and Drug Administration works out purity levels with each manufacturer according to June 2020 guidance for coronavirus vaccines, but it is generally understood that each vaccine batch should reach at least 90 percent. The company has struggled to attain anywhere close to that, one of the people with direct knowledge of the situation said. Another person familiar with the company’s manufacturing process said Novavax has recently shown purity levels hovering around 70 percent. Low purity levels increase the chance that contaminants or unnecessary substances are in the final product, rendering the vaccine less effective or introducing the chance that patients could react to unknown ingredients.\nCOVAX, which recently downgraded its 2021 goal from 2 billion to 1.425 billion doses, has already estimated that it faces a supply shortfall of as many as 1 billion doses in its effort to vaccinate the developing world. If Novavax falters, it could double the deficit through 2022, leaving hundreds of millions of people without immunity against Covid-19 and extending the pandemic.\n“COVAX continues to be challenged for adequate supply … in that context, Novavax’s manufacturing challenges and delays have been massively disruptive,” said Krishna Udayakumar, director of the Duke Global Health Innovation Center.\nThe global coalition is already behind on hundreds of millions of planned doses this month, having shipped just 371 million of its 700 million dose target for October. It is now also at risk of missing its already downgraded 2021 target.\nBetween Novavax and other manufacturers’ hurdles, “COVAX has had to scramble to revise its supply strategy significantly in real time,” Udayakumar said. As a result, global health groups are emphasizing more donations to cover immediate needs, he added.\nIn a statement, Novavax Senior Vice President of Investor Relations and Corporate Affairs Silvia Taylor told POLITICO that the company’s analytical testing methods have been “validated” — but did not answer questions about whether the FDA had signed off on them. The company still plans on filing an emergency use authorization by the end of the year, Taylor said.\n“The vaccine development and regulatory submission processes are highly complex and often require years to advance to the point where we are now. We will fulfill all of our committed doses both in the US and globally,” Taylor said.\nThe White House and the Department of Health and Human Services did not respond to multiple requests for comment.\nBut three people familiar with the matter said they are not confident that the company has the resources needed to reproduce a high-quality vaccine on a consistent basis — a benchmark Novavax must meet before that time. Those same people said Novavax could potentially fix its manufacturing issues and reach full licensure by the end of 2022.\nNovavax — which has never produced a vaccine before — declined to answer specific questions about its product’s purity levels and whether it had been successful in addressing its longstanding manufacturing issues.\nUnlike Pfizer and Moderna, the first manufacturers to launch vaccines using rapidly produced messenger RNA, Novavax is employing the previously used but complicated approach of creating the key ingredient with bug cells. While the process, which involves infecting the cells to produce spike proteins, is familiar to scientists, it is difficult to scale.\nThe revelations about Novavax’s continued manufacturing problems come at a time when only 36 percent of the world is vaccinated and as leaders of developing nations continue to pressure the U.S. to deliver more doses. In Africa alone, only 4.4 percent of the population is vaccinated.\nThat includes some of the continent’s most populous nations, like Nigeria and Uganda, where about 1 percent of citizens are fully vaccinated.\nNovavax is just the latest vaccine maker to run into core production problems after promising to serve as a major vaccine contributor to the developing world. In April, Johnson & Johnsonhalted work at a Baltimore facilityrun by contract manufacturer Emergent BioSolutions after it found that 15 million doses had been accidentally contaminated with ingredients from a separate Covid-19 vaccine.\nJ&J’s manufacturing process has been slow to recover, and to date it has produced just a fraction of the 200 million shots it initially pledged to COVAX by the end of the year, according to records kept by UNICEF.\n“Overpromising and underdelivering is the name of the game for these manufacturers,” said Asia Russell, executive director of international advocacy group Health GAP. “And that’s the infrastructure of the global response, which is terrifying.”\nUnlike Johnson & Johnson, Novavax is a novice in the vaccine world. It has never successfully launched a vaccine, and had struggled financially prior to the pandemic. After a string of drug development failures, it sold its manufacturing facilities in 2019 — a deal that also included parting with 100 employees. In May of that year, Novavax’s stock price dropped as low as 36 cents per share.\nYet the company’s fortunes shifted as Covid-19 took hold. Amid a scramble early in the pandemic to develop a range of vaccine candidates, the Trump administration awarded Novavax $1.6 billion to aid work on its Covid-19 shot — the largest deal given to any Covid-19 vaccine maker at that time.\nThe contract represented a major vote of confidence in Novavax’s capabilities — and a bet that appeared to pay off after late-stage trials showed the vaccine was 90 percent effective against the virus.\nBut even then, senior Trump administration officials on Operation Warp Speed — a group tasked with accelerating vaccine development — repeatedly warned the company that it risked running into problems in scaling up manufacturing of the shot, two people with direct knowledge of those discussions said.\nIn particular, they worried that Novavax would have difficulty ensuring that the vaccine consistently met the FDA’s rigorous quality standards once the vaccine went into mass production — the exact problem that has now stymied the company for months.\n“They rushed the process,” one of the people with knowledge of the matter said. “It’s hard to make. And they can’t make it.”\nTaylor, the Novavax spokesperson, said in a statement that it has incorporated feedback from regulators and has made “tremendous progress with the scale-up of our commercial manufacturing processes.” The company is still on track to produce 150 million doses a month by the end of the year, she said, and has stockpiled tens of millions of doses ahead of regulatory filings in the U.S. and internationally.\nCompany executives in recent presentations to investors have struck a similarly optimistic tone, downplaying the manufacturing snags and predicting it will soon be cleared to begin distributing doses. During aSept. 29 investor event, Chief Commercial Officer John Trizzino said the company had “resolved” its problems and was close to submitting a final regulatory application.\n“We’re really moving along with testing our lots now,” added Gregory Glenn, president of Novavax’s research and development, referring to batches of its vaccine. “We think that this is shortly going to come to a close.”\nU.S. officials working with the company are not as confident, according to three people with knowledge of the matter. Novavax’s manufacturing problems are seen as far more difficult to fix than the sanitary and design concerns that halted production of J&J’s vaccine at the Emergent plant earlier this year, those people said.\nAnd even as the company begins to seek regulatory approval in other countries, there remains doubt in the U.S. that it has solved the fundamental vaccine purity flaws that the people with knowledge said have affected its ability to make doses at plants around the world.\nSeveral vaccine batches have already been discarded, and four people with knowledge of the matter say U.S. officials now no longer expect the company to win FDA sign-off on the vaccine until next year at the earliest.\n“At some level, I think the efficacy was never going to outweigh the risk associated with the impurity that was in there,” said one of the people with knowledge of the matter. “I’m not surprised this is where we are.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":551,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603619690,"gmtCreate":1638404643257,"gmtModify":1638404643467,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Not the time yet","listText":"Not the time yet","text":"Not the time yet","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/603619690","repostId":"2188690505","repostType":4,"isVote":1,"tweetType":1,"viewCount":720,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":850281587,"gmtCreate":1634602242348,"gmtModify":1634602242420,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Very good","listText":"Very good","text":"Very good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/850281587","repostId":"1114416896","repostType":4,"repost":{"id":"1114416896","pubTimestamp":1634601095,"share":"https://www.laohu8.com/m/news/1114416896?lang=&edition=full","pubTime":"2021-10-19 07:51","market":"us","language":"en","title":"Aura and Fat Projects Eye SPAC Listings in New York, Singapore","url":"https://stock-news.laohu8.com/highlight/detail?id=1114416896","media":"Bloomberg","summary":"Singaporean investment firms Aura Group and Fat Projects have agreed to explore launching special pu","content":"<p>Singaporean investment firms&nbsp;Aura Group&nbsp;and Fat Projects have agreed to explore launching special purpose acquisition companies that target technology businesses in the Asia Pacific region.</p>\n<p>“We share the joint thesis that Southeast Asia is one of the most exciting places to invest over the next decade,” Aura co-founder Calvin Ng said in an interview. “The next billion internet users are coming online from this region.”</p>\n<p>Countries such as Thailand, Vietnam and Indonesia are seeing enhanced mobile penetration amid investments in cell towers and other digital infrastructure.</p>\n<p>“We’re a big believer in the Singaporean financial and technology ecosystem, which we expect to continue grow exponentially,” Ng said.</p>\n<p>Aura and Fat Projects are exploring both U.S. and Singapore listings of SPACs within the next six months, Ng said. Terms aren’t finalized, but the partners expect to target vehicles that would amass roughly $100 million in the U.S. and between 150 million Singapore dollars ($111 million) to S$200 million, Ng said.</p>\n<p>“Our combined group will not only gain sustainable access to growth capital but also allow us to systematically tap high-quality companies in the region with speed and precision,” Fat Projects managing partner Tristan Lo said in an emailed statement.</p>\n<p>Lo co-founded the firm with David Andrada. They are co-chief executive officers of&nbsp;Fat Projects Acquisition Corp., their debut SPAC that last week raised $100 million.</p>\n<p>The first Fat Projects vehicle has said it’s seeking to combine with a “technology-led business that can solve diverse challenges in Asia in the areas of supply chain, finance, sustainability/ESG, e-commerce and big data,” or a company that can benefit from the “rapidly growing middle class and their evolving consumption needs.”</p>\n<p>Any “Aura Fat Projects” vehicle to list in Singapore would be among the island nation’s first SPACs. Blank-check firms are&nbsp;poised&nbsp;to revive Singapore’s languishing market for initial public offerings after the nation last month outlined SPAC listing rules that were more lenient that initially expected in an attempt to welcome new issuers.</p>\n<p>Both Aura, which says it currently manages and advises on more than S$951 million in assets, and Fat Projects were founded in Sydney before moving their headquarters to Singapore.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aura and Fat Projects Eye SPAC Listings in New York, Singapore</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAura and Fat Projects Eye SPAC Listings in New York, Singapore\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-19 07:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-10-18/aura-and-fat-projects-eye-spac-listings-in-new-york-singapore?srnd=technology-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Singaporean investment firms Aura Group and Fat Projects have agreed to explore launching special purpose acquisition companies that target technology businesses in the Asia Pacific region.\n“We share ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-10-18/aura-and-fat-projects-eye-spac-listings-in-new-york-singapore?srnd=technology-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.bloomberg.com/news/articles/2021-10-18/aura-and-fat-projects-eye-spac-listings-in-new-york-singapore?srnd=technology-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1114416896","content_text":"Singaporean investment firms Aura Group and Fat Projects have agreed to explore launching special purpose acquisition companies that target technology businesses in the Asia Pacific region.\n“We share the joint thesis that Southeast Asia is one of the most exciting places to invest over the next decade,” Aura co-founder Calvin Ng said in an interview. “The next billion internet users are coming online from this region.”\nCountries such as Thailand, Vietnam and Indonesia are seeing enhanced mobile penetration amid investments in cell towers and other digital infrastructure.\n“We’re a big believer in the Singaporean financial and technology ecosystem, which we expect to continue grow exponentially,” Ng said.\nAura and Fat Projects are exploring both U.S. and Singapore listings of SPACs within the next six months, Ng said. Terms aren’t finalized, but the partners expect to target vehicles that would amass roughly $100 million in the U.S. and between 150 million Singapore dollars ($111 million) to S$200 million, Ng said.\n“Our combined group will not only gain sustainable access to growth capital but also allow us to systematically tap high-quality companies in the region with speed and precision,” Fat Projects managing partner Tristan Lo said in an emailed statement.\nLo co-founded the firm with David Andrada. They are co-chief executive officers of Fat Projects Acquisition Corp., their debut SPAC that last week raised $100 million.\nThe first Fat Projects vehicle has said it’s seeking to combine with a “technology-led business that can solve diverse challenges in Asia in the areas of supply chain, finance, sustainability/ESG, e-commerce and big data,” or a company that can benefit from the “rapidly growing middle class and their evolving consumption needs.”\nAny “Aura Fat Projects” vehicle to list in Singapore would be among the island nation’s first SPACs. Blank-check firms are poised to revive Singapore’s languishing market for initial public offerings after the nation last month outlined SPAC listing rules that were more lenient that initially expected in an attempt to welcome new issuers.\nBoth Aura, which says it currently manages and advises on more than S$951 million in assets, and Fat Projects were founded in Sydney before moving their headquarters to Singapore.","news_type":1},"isVote":1,"tweetType":1,"viewCount":519,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":829404697,"gmtCreate":1633530962458,"gmtModify":1633530962530,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"why sell???","listText":"why sell???","text":"why sell???","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/829404697","repostId":"1126696993","repostType":2,"isVote":1,"tweetType":1,"viewCount":578,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606853487,"gmtCreate":1638861086065,"gmtModify":1638861086179,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"EV to the moon","listText":"EV to the moon","text":"EV to the moon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606853487","repostId":"2189682681","repostType":4,"repost":{"id":"2189682681","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1638857613,"share":"https://www.laohu8.com/m/news/2189682681?lang=&edition=full","pubTime":"2021-12-07 14:13","market":"us","language":"en","title":"Tesla's Musk says Biden's EV bill shouldn't pass","url":"https://stock-news.laohu8.com/highlight/detail?id=2189682681","media":"Reuters","summary":"SAN FRANCISCO, Dec 6 (Reuters) - Tesla Inc CEO Elon Musk said on Monday that the U.S. Congress shoul","content":"<p>SAN FRANCISCO, Dec 6 (Reuters) - Tesla Inc&nbsp;CEO Elon Musk said on Monday that the U.S. Congress should not approve the Biden administration's bill to boost subsidies for electric vehicles (EVs), saying the proposal would worsen the country's budget deficit.</p>\n<p>The billionaire entrepreneur is escalating criticism about the administration and Democrats for a proposal to give union-made, U.S.-built electric vehicles an additional $4,500 tax incentive. Tesla and foreign automakers do not have unions at their U.S. factories.</p>\n<p>\"Honestly, it might be better if the bill doesn't pass,\" Musk said at the WSJ CEO Council Summit.</p>\n<p>\"I'm literally saying get rid of all subsidies,\" he said, adding that the government should I think just try to get out of the way and not impede progress.\"</p>\n<p>He also reiterated opposition to a proposal by Democrats to tax billionaires. \"It does not make sense to take the job of capital allocation away from people who have demonstrated great skill ... and give it to, you know, an entity that has demonstrated very poor skill in capital allocation, which is the government.\"</p>\n<p>Musk also said his brain-chip startup, Neuralink hopes to begin human trials next year pending approval of the U.S. Food and Drug Administration. \"I think we have a chance with Neuralink of being able to restore full body functionality to someone who has a spinal cord injury.\"</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla's Musk says Biden's EV bill shouldn't pass</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla's Musk says Biden's EV bill shouldn't pass\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-07 14:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SAN FRANCISCO, Dec 6 (Reuters) - Tesla Inc&nbsp;CEO Elon Musk said on Monday that the U.S. Congress should not approve the Biden administration's bill to boost subsidies for electric vehicles (EVs), saying the proposal would worsen the country's budget deficit.</p>\n<p>The billionaire entrepreneur is escalating criticism about the administration and Democrats for a proposal to give union-made, U.S.-built electric vehicles an additional $4,500 tax incentive. Tesla and foreign automakers do not have unions at their U.S. factories.</p>\n<p>\"Honestly, it might be better if the bill doesn't pass,\" Musk said at the WSJ CEO Council Summit.</p>\n<p>\"I'm literally saying get rid of all subsidies,\" he said, adding that the government should I think just try to get out of the way and not impede progress.\"</p>\n<p>He also reiterated opposition to a proposal by Democrats to tax billionaires. \"It does not make sense to take the job of capital allocation away from people who have demonstrated great skill ... and give it to, you know, an entity that has demonstrated very poor skill in capital allocation, which is the government.\"</p>\n<p>Musk also said his brain-chip startup, Neuralink hopes to begin human trials next year pending approval of the U.S. Food and Drug Administration. \"I think we have a chance with Neuralink of being able to restore full body functionality to someone who has a spinal cord injury.\"</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2189682681","content_text":"SAN FRANCISCO, Dec 6 (Reuters) - Tesla Inc CEO Elon Musk said on Monday that the U.S. Congress should not approve the Biden administration's bill to boost subsidies for electric vehicles (EVs), saying the proposal would worsen the country's budget deficit.\nThe billionaire entrepreneur is escalating criticism about the administration and Democrats for a proposal to give union-made, U.S.-built electric vehicles an additional $4,500 tax incentive. Tesla and foreign automakers do not have unions at their U.S. factories.\n\"Honestly, it might be better if the bill doesn't pass,\" Musk said at the WSJ CEO Council Summit.\n\"I'm literally saying get rid of all subsidies,\" he said, adding that the government should I think just try to get out of the way and not impede progress.\"\nHe also reiterated opposition to a proposal by Democrats to tax billionaires. \"It does not make sense to take the job of capital allocation away from people who have demonstrated great skill ... and give it to, you know, an entity that has demonstrated very poor skill in capital allocation, which is the government.\"\nMusk also said his brain-chip startup, Neuralink hopes to begin human trials next year pending approval of the U.S. Food and Drug Administration. \"I think we have a chance with Neuralink of being able to restore full body functionality to someone who has a spinal cord injury.\"","news_type":1},"isVote":1,"tweetType":1,"viewCount":489,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":851838102,"gmtCreate":1634890474595,"gmtModify":1634890474595,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AMD\">$AMD(AMD)$</a>&nbsp;up up up!!!&nbsp;","listText":"<a href=\"https://laohu8.com/S/AMD\">$AMD(AMD)$</a>&nbsp;up up up!!!&nbsp;","text":"$AMD(AMD)$ up up up!!!","images":[{"img":"https://static.tigerbbs.com/2da1478496dda3d23161f71934bb6c2b","width":"1080","height":"2375"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/851838102","isVote":1,"tweetType":1,"viewCount":504,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":829410404,"gmtCreate":1633532533184,"gmtModify":1633532533259,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"But why stock price still drop??&nbsp;","listText":"But why stock price still drop??&nbsp;","text":"But why stock price still drop??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/829410404","repostId":"1169679917","repostType":2,"isVote":1,"tweetType":1,"viewCount":637,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}